Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company, 2609 [2024-00692]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than February 15, 2024.
A. Federal Reserve Bank of Chicago
(Colette A. Fried, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690–1414.
Comments can also be sent
electronically to
Comments.applications@chi.frb.org:
1. Northstar Financial Group, Inc.,
Bad Axe, Michigan; to acquire
Mainstreet Community Bank of Florida,
DeLand, Florida.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024–00691 Filed 1–12–24; 8:45 am]
ddrumheller on DSK120RN23PROD with NOTICES1
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Jkt 262001
[FR Doc. 2024–00692 Filed 1–12–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Supplemental Evidence and Data
Request on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition
FEDERAL RESERVE SYSTEM
18:57 Jan 12, 2024
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
Agency for Healthcare Research and
Quality
BILLING CODE P
VerDate Sep<11>2014
Washington, DC 20551–0001, not later
than January 31, 2023.
A. Federal Reserve Bank of
Philadelphia (William Spaniel, Senior
Vice President) 10 Independence Mall,
Philadelphia, Pennsylvania 19106.
Comments can also be sent
electronically to
comments.applications@phil.frb.org:
1. Kenneth R. Lehman, Fort
Lauderdale, Florida; to acquire voting
shares of Blue Ridge Bankshares, Inc.,
Charlottesville, Virginia, and thereby
indirectly acquire voting shares of Blue
Ridge Bank, National Association,
Martinsville, Virginia.
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submission.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
The Effect of Dietary Digestible
Carbohydrate Intake on Risk of Type 2
Diabetes, Growth, Size, and Body
Composition, which is currently being
conducted by the AHRQ’s Evidencebased Practice Centers (EPC) Program.
Access to published and unpublished
pertinent scientific information will
improve the quality of this review.
DATES: Submission Deadline on or
before February 15, 2024.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
SUMMARY:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
2609
Improvement Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane,
Mail Stop 06E77D, Rockville, MD
20857.
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition. AHRQ is conducting
this review pursuant to Section 902 of
the Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition. The entire research
protocol is available online at: https://
effectivehealthcare.ahrq.gov/products/
effect-dietary-digestible.
This is to notify the public that the
EPC Program would find the following
information on The Effect of Dietary
Digestible Carbohydrate Intake on Risk
of Type 2 Diabetes, Growth, Size, and
Body Composition helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
E:\FR\FM\16JAN1.SGM
16JAN1
]]>Agencies
[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Page 2609]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00692]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices; Acquisitions of Shares of a Bank
or Bank Holding Company
The notificants listed below have applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and Sec. 225.41 of the Board's
Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank
holding company. The factors that are considered in acting on the
applications are set forth in paragraph 7 of the Act (12 U.S.C.
1817(j)(7)).
The public portions of the applications listed below, as well as
other related filings required by the Board, if any, are available for
immediate inspection at the Federal Reserve Bank(s) indicated below and
at the offices of the Board of Governors. This information may also be
obtained on an expedited basis, upon request, by contacting the
appropriate Federal Reserve Bank and from the Board's Freedom of
Information Office at https://www.federalreserve.gov/foia/request.htm.
Interested persons may express their views in writing on the standards
enumerated in paragraph 7 of the Act.
Comments regarding each of these applications must be received at
the Reserve Bank indicated or the offices of the Board of Governors,
Ann E. Misback, Secretary of the Board, 20th Street and Constitution
Avenue NW, Washington, DC 20551-0001, not later than January 31, 2023.
A. Federal Reserve Bank of Philadelphia (William Spaniel, Senior
Vice President) 10 Independence Mall, Philadelphia, Pennsylvania 19106.
Comments can also be sent electronically to
[email protected]:
1. Kenneth R. Lehman, Fort Lauderdale, Florida; to acquire voting
shares of Blue Ridge Bankshares, Inc., Charlottesville, Virginia, and
thereby indirectly acquire voting shares of Blue Ridge Bank, National
Association, Martinsville, Virginia.
Board of Governors of the Federal Reserve System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024-00692 Filed 1-12-24; 8:45 am]
BILLING CODE P
